Sales Goals and Performance - The company has set internal sales targets for 2026, which will not be disclosed externally, and is optimistic about achieving good performance based on refined operations in 2025 [2] - The sales ratio of online to offline channels has improved from 80:20 in the 2025 semi-annual report, with further details to be revealed in the 2025 annual report [2][3] - The company reported good performance during the 3.8 promotional event, aligning with expectations, and aims to enhance sales through active participation in platform activities [3] Product Development and Innovation - The company has a robust pipeline of new products for 2026, including various forms such as dressings, masks, lotions, creams, and serums, with specifics to be confirmed based on actual launches [3] - The R&D team has expanded significantly compared to early 2025, with improvements in the educational background of its members [3] Profitability and Business Strategy - The company plans to strengthen its offline business in 2026, which has a higher net profit margin compared to online sales, and is confident in achieving better overall profitability [3] - The company is considering stock incentive plans but has not set a specific timeline for implementation, with future updates to be disclosed in accordance with regulatory requirements [3] Dividend and Financial Planning - The dividend plan for the current year has not yet been determined, and stakeholders are advised to monitor announcements scheduled for April 23, 2026 [3] General Information - The investor relations activity did not involve any major information that needs to be disclosed [3]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Group 1 - The company, Fuhua, plans to register 48 cosmetic products by 2025, covering various forms such as water, lotion, cream, and essence [2][5] - Detailed product registration information can be found on the National Medical Products Administration website [2][5]

Core Viewpoint - The article discusses the evolution and achievements of the Chinese skincare brand, Ai Er Bo Shi, particularly in the field of microbiome science in skincare, emphasizing its journey from research to consumer products and its role in establishing a scientific and cultural identity for Chinese brands on the global stage [3][4][6]. Group 1: Research and Development - Since 2020, Ai Er Bo Shi has held an annual "Skin Microecology Conference," which has become a significant platform for research, academic exchange, and industry transformation, witnessing the brand's growth and expanding the industry's perspective [6]. - The brand has developed the first Chinese skin microbiome scientific skincare platform and established a database correlating skin microbiota with physiological parameters, marking a shift from theoretical discussions to applied research and industry connections [6][12]. - The "287 Barrier Bacteria" was identified as a key strain with significant repair functions, representing a critical step in China's foundational research on skin microbiomes [14][15]. Group 2: Product Innovation - Ai Er Bo Shi successfully applied the "287 Barrier Technology" in its new product line, which includes water, lotion, cream, and masks, demonstrating significant repair effects validated by user testing [16][19]. - The products utilize a combination of advanced ingredients and technologies to provide a comprehensive skin barrier repair solution, translating scientific mechanisms into tangible consumer experiences [19][21]. Group 3: Brand Evolution and Strategy - The brand announced a comprehensive renewal, entering the "Scientific Guardian, Renewed Life" 3.0 era, which emphasizes a holistic upgrade in visual aesthetics, user experience, and social responsibility [22][26]. - The renewal process involved deep consumer engagement to enhance product functionality and design, reflecting a commitment to user-centric innovation [25][26]. - Ai Er Bo Shi aims to position itself not only as an innovator in microbiome skincare but also as a socially responsible technology brand, integrating scientific research with cultural values and community engagement [26].